Market Overview

Stifel Drops Bullish Zoetis Thesis After 108% Outperformance

Stifel Drops Bullish Zoetis Thesis After 108% Outperformance
Related ZTS
The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Paws Up: The First Pets ETF Is Here

The bullish case for Zoetis Inc (NYSE: ZTS) has come to an end after the stock outperformed the S&P 500 index by 108 percent since spinning out from Pfizer Inc. (NYSE: PFE), according to Stifel.

The Analyst

Stifel's Jonathan Block downgraded Zoetis from Buy to Hold with a $95 price target. 

The Thesis

Zoetis' management team deserves credit for "near-flawless" execution over the years, but the time to buy the stock has passed, Block said in the downgrade note. (See his track record here.)

On the product side, the company's "Big 3" products — Apoquel, Cytopoint and Simparica — accounted for 50 percent of revenue growth in 2016 and 56 percent of revenue growth in 2017. The law of large numbers suggests a slowdown of growth in 2019 and 2020, and any new material product cycle in the pipeline is unlikely to be seen within the next 18 months, the analyst said. 

The cattle business, especially dairy, remains under pressure and comps will become increasingly difficult in the coming quarters, Block said. It's hard to imagine a scenario of revenue upside with the product cycle being several years old, he said. 

Zoetis shares are trading at 27 times 2019 estimated EPS and 24 times 2020 EPS estimated EPS, which implies a 57-percent premium to the S&P 500 index versus the three-year average of 37 percent, Block said. A premium valuation is warranted, but at current levels the case to justify incremental expansion is difficult to make, he said. 

Price Action

Zoetis shares were trading down 2.35 percent to $89.93 off the open Wednesday. 

Related Links:

Zoetis Downgraded As Valuation Approaches Morgan Stanley's Price Target

Analyst: Zoetis Deserves To Trade At A Premium

Latest Ratings for ZTS

Nov 2018JP MorganMaintainsOverweightOverweight
Oct 2018JP MorganUpgradesNeutralOverweight
Aug 2018Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for ZTS
View the Latest Analyst Ratings

Posted-In: cattle Dairy Jonathan Block Pet CareAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (PFE + ZTS)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

10 Biggest Price Target Changes For Wednesday

EUR/USD Forecast: Trump's Troubles Are Not Enough, Fed Fear Weighs